Ustekinumab: all 102 studies that test it

Page 1 of 2. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.

• Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingNCT07352566Phase 4
• De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative ColitisRecruitingNCT07303686Phase 4
• Biologics in Folliculitis Decalvans : an Adaptative Trial ResearchNot yet recruitingNCT07268534Phase 2
• Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingNCT07138898Phase 2
• Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer PatientsRecruitingNCT06807593Phase 2
• Efficacy and Safety of Dual-targeted Therapy With Upadacitinib and Ustekinumab Versus Intensified Ustekinumab Therapy in Crohn's DiseaseRecruitingNCT06520397Phase 4
• Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative ColitisRecruitingNCT06453317Phase 2
• Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis.RecruitingNCT05725876Phase 1
• Development of Predictive Psoriasis Response Endotypes Using Single Cell TranscriptomicsRecruitingNCT05270733Phase 4
• Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic ArthritisRecruitingNCT04610476Phase 3
• Effects of Treatment With Biological Agents on Vascular and Cardiac Function in PsoriasisRecruitingNCT02144857Phase 4
• A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)TerminatedNCT04882072Phase 3Results posted
• A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisCompletedNCT04761627Phase 3Results posted
• A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's DiseaseCompletedNCT04673357Phase 3Results posted
• Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor TreatmentCompletedNCT04632927Phase 3Results posted
• A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)CompletedNCT04630028Phase 3Results posted
• Induction Optimization With Stelara for Crohn's DiseaseTerminatedNCT04629196Phase 4Results posted
• A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisCompletedNCT04607980Phase 3Results posted
• An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With IchthyosesCompletedNCT04549792Early Phase 1Results posted
• Loss of RESponse to Ustekinumab Treated by Dose EscalationCompletedNCT04245215Phase 3Results posted
• Pilot Trial of Ustekinumab for Primary Sjögren's SyndromeCompletedNCT04093531Phase 1Results posted
• A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care TreatmentsTerminatedNCT03981744Phase 3Results posted
• Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)CompletedNCT03881059Phase 2Results posted
• A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's DiseaseCompletedNCT03782376Phase 3Results posted
• A Study of Ustekinumab in Participants With Active Systemic Lupus ErythematosusTerminatedNCT03517722Phase 3Results posted
• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseaseActive, not recruitingNCT03466411Phase 2/3Results posted
• Safety and Efficacy of Adalimumab Versus Ustekinumab for One YearCompletedNCT03464136Phase 3Results posted
• Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With UstekinumabCompletedNCT03107793Phase 3Results posted
• Ustekinumab for the Treatment of Giant Cell ArteritisTerminatedNCT02955147Phase 1/2Results posted
• Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)CompletedNCT02911116Phase 2Results posted
• Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's DiseaseCompletedNCT02877134Phase 2Results posted
• An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of AgeCompletedNCT02698475Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial SpondyloarthritisTerminatedNCT02438787Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial SpondyloarthritisTerminatedNCT02437162Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT02407236Phase 3Results posted
• An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial SpondyloarthritisTerminatedNCT02407223Phase 3Results posted
• A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus ErythematosusCompletedNCT02349061Phase 2Results posted
• A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to UstekinumabCompletedNCT02203032Phase 3Results posted
• Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable ImmunodeficiencyCompletedNCT02199496Phase 1/2Results posted
• Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)CompletedNCT02187172Phase 4Results posted
• A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic DermatitisCompletedNCT01945086Phase 2Results posted
• Pilot Study of Ustekinumab for Subjects With Chronic Atopic DermatitisCompletedNCT01806662Phase 2Results posted
• Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host DiseaseCompletedNCT01713400Phase 2Results posted
• A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate TherapyCompletedNCT01645280Phase 2Results posted
• A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque PsoriasisCompletedNCT01550744Phase 3Results posted
• The Quality of Life Study in Psoriasis Patients After Ustekinumab TreatmentCompletedNCT01511315Phase 4Results posted
• A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic AcidCompletedNCT01389973Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)CompletedNCT01369355Phase 3Results posted
• A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)CompletedNCT01276847Phase 1Results posted
• A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)CompletedNCT01090427Phase 3Results posted
• Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar PsoriasisCompletedNCT01090063Not applicableResults posted
• A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF AgentsCompletedNCT01077362Phase 3Results posted
• A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic ArthritisCompletedNCT01009086Phase 3Results posted
• A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With PsoriasisCompletedNCT01008995Phase 3Results posted
• A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With SarcoidosisCompletedNCT00955279Phase 2Results posted
• A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF TherapyCompletedNCT00771667Phase 2Results posted
• A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type PsoriasisCompletedNCT00747344Phase 3Results posted
• An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque PsoriasisCompletedNCT00723528Phase 3Results posted
• An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque PsoriasisCompletedNCT00454584Phase 3Results posted
• A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type PsoriasisCompletedNCT00320216Phase 2Results posted
• A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe PsoriasisCompletedNCT00307437Phase 3Results posted
• A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type PsoriasisCompletedNCT00267969Phase 3Results posted
• An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic ArthritisCompletedNCT00267956Phase 2Results posted
• A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's DiseaseCompletedNCT00265122Phase 2Results posted
• A Safety and Efficacy Study of CNTO1275 in Patients With Multiple SclerosisCompletedNCT00207727Phase 2Results posted
• Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic SyndromeCompletedNCT07582991Phase 2
• A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's DiseaseActive, not recruitingNCT06045754Phase 4
• Using a Contact Dermatitis Model With Biologic Medications to Study Skin InflammationActive, not recruitingNCT05535738Phase 2/3
• An Open-Label Extension and Long-term Efficacy and Safety Monitoring Study of Patients With Crohn's Disease Previously Included in the Loss of RESponse to Ustekinumab Treated by Dose Escalation StudyCompletedNCT05299931Phase 3
• A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or PsoriasisCompletedNCT05252533Phase 1
• A Long-term Extension Study of Ustekinumab in Pediatric ParticipantsActive, not recruitingNCT05092269Phase 3
• A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic ArthritisCompletedNCT05083182Phase 3
• A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's DiseaseCompletedNCT05029921Phase 4
• Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in ChildrenStatus unknownNCT04996485Phase 4
• A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy ParticipantsCompletedNCT04816513Phase 1
• A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of America (US) Sourced Stelara in Healthy SubjectsCompletedNCT04772274Phase 1
• Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)CompletedNCT04744363Phase 1
• A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque PsoriasisCompletedNCT04595409Phase 3
• Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell TransplantActive, not recruitingNCT04572815Phase 2
• USTekinumab in Fistulising Perianal Crohn's Disease (USTAP)Active, not recruitingNCT04496063Phase 4
• Efficacy and Safety of Ustekinumab in Bullous PemphigoidCompletedNCT04117932Phase 2
• Stelara fOr ChRonic AntibioTic rEfractory pouchitiSCompletedNCT04089345Phase 3
• A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus ErythematosusWithdrawnNCT04060888Phase 3
• Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese ParticipantsCompletedNCT04030533Phase 1
• Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2)Active, not recruitingNCT03941132Phase 2/3
• Identification by Cytometry by Mass of Predictive Immunological Profiles of Answer to Treatmentby Biotherapics for Patients With Crohn's DiseaseWithdrawnNCT03712826Not applicable
• Personalized Therapies in Inflammatory Complex DiseaseCompletedNCT03651518Phase 2
• Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin LesionsCompletedNCT03629379Phase 4
• Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory PathologyCompletedNCT03366142Phase 1/2
• A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative ColitisTerminatedNCT03358706Phase 1
• A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's DiseaseCompletedNCT02968108Phase 1
• The Difference of Microparticles in Patients With Psoriasis Vulgaris Who Received Stelara(Ustekinumab)Status unknownNCT02693470Phase 4
• Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet DiseaseCompletedNCT02648581Phase 2
• Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 MelitisCompletedNCT02204397Phase 2
• A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial FormulationsCompletedNCT02156375Phase 1
• Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1DStatus unknownNCT02117765Phase 1/2
• A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis SuppurativaCompletedNCT01704534Phase 2
• Ustekinumab for Active Sight-Threatening UveitisWithdrawnNCT01647152Phase 1/2
• A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp PsoriasisStatus unknownNCT01558310Phase 4
• Ustekinumab for the Treatment of Patients With Active Ankylosing SpondylitisCompletedNCT01330901Phase 2

← Ustekinumab overview